If the combo results are great, PPS should rise by itself (i.e. w/o partnership) to a decent level, and obviously higher if there's a partnership. Remember only ~30% patients respond to Keytruda. If ONCS can make that better, the market will not just ignore ONCS even before partnership. The fact that they are laying out accelerated approval trial design, and not just mentioning AA in their investor slides makes me believe the combo data is very good. September will be boring but starting October it could get more exciting. Hang in there.
News 
Market Data 
Discover 
